You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

980 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    cyclophosphamide - oral tablets
Oct 2023
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Nov 2021
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab Deruxtecan - Unresectable Locally Advanced or Metastatic Breast Cancer
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Sacituzumab Govitecan - Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
Sep 2023
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
Sep 2023
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Nov 2023
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Nov 2023

Pages